About US
Contact us
-
FDA hammers Mylan sterile injectable plants for serious contamination issuesThe recent recall of 8 lots of injectable cancer drugs, some of which Mylan ($MYL) made for client Pfizer ($PFE), was just a prelude to anFDAwarning letter, it turns out. The agency today posted the l2015/8/19
-
Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partnersWho should serial buyer Allergan ($AGN) pick up next? It's the question on the minds of many industry watchers--including Evercore ISI analyst Umer Raffat, who polled investors last week. And while th2015/8/19
-
Will docs jump on new biosims? Survey shows they'll need some nudgingDrugmakers are well aware of the biosimilars threatening to steal sales and market share from some of the world's best-selling biologics. Doctors, though? Not so much, a new report suggests. Doctor2015/8/18
-
Mylan, Disney expand allergy-fighting partnership with new websiteParents whose children have potentially life-threatening allergies now have some new resources--thanks to Mylan ($MYL) and Disney ($DIS), which have teamed up to launchMyAllergyKingdom.com. There, the2015/8/18
-
FDA approves Purdue's OxyContin for use in youth aged 11 to 16The addictive qualities of the powerful pain drugOxyContinhave made it controversial, but theFDAhas now approved it for youth 11 to 16 after asking makerPurdue Pharmato study its use in that age group2015/8/17
-
Probing lawmakers grill Valeant on price hikesA pair of lawmakers is taking a look into recent drug price increases--and as part of the investigation, it wants some information from Valeant. On Friday, Rep. Elijah Cummings (D-MD) and Sen. Bernie2015/8/17
-
GSK says people and products were never in danger from Legionella bacteria in cooling towersGlaxoSmithKline ($GSK) says that the people and products at its manufacturing site in Zebulon, NC, were never in peril from the bacteria for Legionnaires' disease detected this week in two cooling tow2015/8/14
-
State-level price caps? Massachusetts drug-cost pushback breaks new groundMassachusetts is joining the state-level push to tamp downdrug prices. Lawmakers are proposing new disclosures about pharma's pricing decisions, just as they are in other states. But unlike California2015/8/14
-
Patent challenger Bass shrugs off Celgene's attack on his short-selling motivesMoney makes the world go round--the patent world, that is. That's the word from hedge funderKyle Bass, who has been targeting drug patents he calls "low quality," and shorting pharma stocks along the2015/8/13
-
How slow can Big Pharma go in emerging markets?ndustry watchers have pointed to a slowdown in pharma's emerging markets growth as a worrying sign for companies that have been heavily targeting developing nations while the U.S. and European markets2015/8/13